Ausun Pharm(SH:603229)2021-04-27 16:00Financial Performance - Net profit attributable to shareholders was ¥43,878,486.62, representing a significant increase of 109.15% year-on-year[12]. - Operating revenue for the period was ¥143,993,120.12, marking an 81.19% increase compared to the same period last year[12]. - Basic earnings per share were ¥0.18, doubling from ¥0.09 in the same period last year, reflecting a 100% increase[12]. - The net profit for the first quarter of 2021 was CNY 43,878,486.62, representing a 109.15% increase compared to the same period last year[22]. - Total profit for Q1 2021 was CNY 49,215,417.58, an increase from CNY 19,857,794.17 in Q1 2020[46]. - The company reported a net profit of ¥336,548,716.34 for Q1 2021, compared to ¥292,566,488.35 in Q1 2020, an increase of 15.0%[36]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,382,342,793.46, a slight increase of 0.05% compared to the previous year[12]. - The company’s total liabilities increased, with contract liabilities rising by 64.81% to ¥4,174,772.22 from ¥2,533,017.61, indicating higher advance payments received[20]. - The total liabilities decreased to ¥205,462,094.86 from ¥225,067,026.27, a reduction of 8.1%[36]. - The company’s non-current assets totaled CNY 454,153,569.72, an increase from CNY 401,760,921.72 year-over-year[28]. - Other non-current assets increased by 149.43% to ¥61,715,554.90 from ¥24,742,696.63, mainly due to payments for land acquisition[20]. Cash Flow - The net cash flow from operating activities was negative at -¥1,903,712.91, a decrease of 111.34% compared to the previous year[12]. - Cash flow from operating activities showed a net outflow of CNY -1,903,712.91, a decrease of 111.34% compared to the first quarter of 2020[22]. - Cash inflow from operating activities totaled CNY 101,912,010.85 in Q1 2021, down from CNY 133,140,118.15 in Q1 2020, reflecting a decrease of approximately 23.4%[53]. - Cash flow from investing activities showed a net outflow of CNY 231,402,392.49 in Q1 2021, worsening from a net outflow of CNY 38,938,955.89 in Q1 2020[53]. - The ending cash and cash equivalents balance for Q1 2021 was CNY 434,921,397.29, up from CNY 262,481,062.41 in Q1 2020[53]. Shareholder Information - The total number of shareholders at the end of the reporting period was 9,766, with the top ten shareholders holding a significant portion of the shares[14]. - The largest shareholder, Zheng Zhiguo, held 57.38% of the shares, amounting to 137,262,852 shares[14]. Operating Costs and Expenses - Operating costs rose by 75.90% to ¥64,205,718.01 from ¥36,501,886.07, reflecting increased sales volume[20]. - The company reported a significant increase in income tax expenses, totaling CNY 5,233,189.59, up 279.38% due to increased taxable income[22]. - The company reported a 45.53% decrease in selling expenses to ¥910,684.60 from ¥1,672,044.76, attributed to reduced consulting service fees[20]. - The company's operating costs for Q1 2021 were CNY 63,320,762.25, up from CNY 36,501,886.07 in Q1 2020[46]. Other Income and Expenses - The company received government subsidies amounting to ¥938,020.54, which are closely related to its normal business operations[12]. - The company reported a non-operating income of ¥93,897.79, contributing to its overall financial performance[14]. - Financial expenses improved by 36.55%, with a loss of ¥3,683,285.03 compared to a loss of ¥5,805,133.37 in the previous year, due to a smaller increase in the USD to RMB exchange rate[20]. - The company’s investment income showed a significant decline, with a loss of ¥5,111,727.02 compared to a gain of ¥302,856.60 in the previous year, primarily due to losses from expired foreign exchange swaps[20].